Brinter and Puredyne Launch Visco Bio

Guide:
March 8, 2022 Finnish
biology
Printing company Brinter and extrusion technology developer Puredyne announce new 3D
medical
Bioprinter head Visco Bio, intended to push3D bioprinting. New Technology Visco Bio and Brinter 3D bioprintingMachines are backward compatible and aim to make bioprinting more accessible and affordable for everyone.

In the field of bioprinting, customers expect expensive medical materials to be kept to a minimum. As a result, the Visco Bio printer head features a new dispensing geometry, and the modular print head is able to extrude a more precise and constant volume, resulting in virtually zero dead volume.
The original meaning of dead volume is the void volume in the column that is not occupied by the stationary phase, that is, the volume of the mobile phase in the column. But in the actual measurement, it includes the extra-column dead volume (the space between the pipes and connectors in the chromatograph and the space between the sampling system and the detector). When the extra-column volume is small, it can be ignored.

Brinter and 3D Bioprinting

Founded in 2020, Brinter is a spin-off company of 3DTech Ltd, specializing in the development of 3D bioprinters, modules and bio-inks for customers in the pharmaceutical, biotechnology, scientific research and cosmetic industries. The company is currently active in more than ten countries including the United States, the United Kingdom and Germany, and cooperates with many companies and universities. Clients include Nanoform, Johannes Gutenberg University of Mainz, University of Oulu, University of Turku, Åbo Akademi, Tampere University and University of Helsinki.

The printing system will also use a new sterilizing blue light module. Essentially, it enables the safe bioprinting of tissue structures and drugs while minimizing the need for dedicated clean rooms. “This printhead complies with (GMP) specifications
standard
, using one cartridge per material, works with our released sterilizing blue light modules without cross-contamination. Likewise, researchers, the pharmaceutical industry and universities will benefit from the changes brought about by Visco Bio’s new technology, which increases the precision and repeatability of the printing process,” said Tomi Kalpio, CEO of Brinter.

Brinter’s first bioprinter is the flagship Brinter One, capable of printing3D printingA wide variety of materials and highly complex tissue structures provide all the essential functions required for bioprinting. It works by depositing layers of cell-laden hydrogels into tumor structures as well as cancerous and cartilaginous microtissues.Can3D printingHard and soft materials while being portable enough to be packaged and installed in different labs in minutes.

Last year, Brinter also received 1.2 million euros worth of seed funding to help them better develop their business, hoping to better serve the US and European medical markets through its bioprinting product technology.

Recently, the company also introduced an entry-level Brinter Core bioprinter. It was developed to make bioprinting as easy to use as possible, at half the size and cost of its predecessor, and capable of fabricating complex multi-material tissue structures.

New technology will boost ambition to 3D print human parts like hearts and kidneys

Felix Gruber, Business Development Manager at Puredyne, said: “Brinter has been a very innovative and strong business partner for us, with whom we have built a relationship for many years. Puredyne printheads are based on proven progressive cavity technology and are available in A whole new level of precision is achieved in extruded bioprinting. In addition, we address the process and material flexibility needed for printing operators to handle low to high viscosity biomaterials.”

Tomi Kalpio, CEO of Brinter, added: “This technology is in line with their company’s vision to improve our quality of life by shortening and improving biomanufacturing. This new technology will advance their future research into 3D printed hearts and kidneys. ambitions for parts such as human bodies, as well as more personalised treatments through cancer research and drug testing.”

(responsible editor: admin)